Lupin Limited · NSE:LUPIN
Lupin — Q3 FY25 Earnings Presentation
22 slides from Lupin's earnings presentation, Feb 12, 2025
Slide 1: Exchange filing cover letter
February 12, 2025 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation - Q3 FY25. Dear Sir
Slide 2: Investor Presentation Q3 FY25
Investor Presentation Q3 FY25 Feb 12, 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Q3FY25 Performance
LUPIN Q3FY25 Perforn
Slide 5: Q3FY25: Key Growth Metrics
Q3FY25: Key Growth Metrics Continued strong Operating Performance Key Metrics Business Performance INR India North America 56,186 mn 19,305 mn 21,213 mn Sales 12% YoY 12% YoY 11% YoY 13,659 mn 24.3% Emerging Markets EMEA EBITDA1 Margin 4,508 mn 6,249 mn -5% YoY 21% YoY 34% YoY API ROW 8,552 mn 15.2%
Slide 6: Q3FY25: Key Developments
Q3FY25: Key Developments Consistent improvement in margins Financials Key Approvals / Launches US FDA Sales* and EBITDA margin Trajectory Prednisolone Launched Emtricitabine & Approval 60,000 55,143 54,970 56,186 30.0% Acetate with CGT Tenofovir with shared 50,799 48,951 Ophthalmic Soln. exclusivity
Slide 7: Q3FY25: Financial Snapshot
Q3FY25: Financial Snapshot Sales Mix Key Financials INR mn Revenue (In INR mn and %) India, North Q3 FY25 Q3 FY24 Q2 FY25 19,305 America, 34% 21,213 Sales 56,186 50,799 54,970 38% API, 2,891 EBITDA1 13,659 10,220 13,083 5% Emerging ROW, EMEA, Markets, 2,020 6,249 4,508 Net Income2 8,552 6,131 8,526
Slide 8: India: Outperforming market growth
India: Outperforming market growth India business grew ~12% YoY Leveraging chronic leadership India Sales (INR mn) 19,259 20,096 19,305 17,251 16,015 #2 rank #3 rank #3 rank Respiratory2 Diabetes Care2 Cardiac2 • Chronic segment1; ~65% of sales in Q3 vs ~62% in Q2 FY25 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3
Slide 9: India: Amplifying our Core
India: Amplifying our Core Lupin prescription business is positioned to outperform Enabling end to end healthcare ecosystem and access IPM with key drivers in place for the patient Enhancing penetration and reach CHC Portfolio catering to GI, • Maximizing Chronic therapy focus VMS, Cough/cold therap
Slide 10: North America: Delivering on Complex Generics
North America: Delivering on Complex Generics Leadership: ~4% TRx Consistent Sales trajectory Growing Respiratory portfolio volume share in U.S.1 US Sales ($ mn) #3 #1 212 209 227 220 235 29.6% 23% 30.3% in the US1 in 50 products2 Tiotropium Albuterol Arfomoterol Maintaining Top 3 in 103 Q3 Q4 Q1 Q2
Slide 11: Other Markets: Key Highlights
Other Markets: Key Highlights Consistent growth in Key Markets • Strong double-digit growth in Germany and UK • BRL ~64 mn sales4 in Q3FY25 EU • Growth driven by key products Brazil (~19% YoY growth) like Luforbec® and NaMuscla® • Rank 2nd in reference market3 • 8th largest generics player1 • Revenu
Slide 12: Innovation and Quality
Innovation and Quality R&D pivoting towards complex generics and Achieve Best-in-Class Quality biosimilars Substantial Capabilities to become CGx powerhouse Recent Track Record • Inhalation: Global presence with end-to-end capabilities Successful outcomes in last 9 months of MDIs, DPIs, Soft-Mist In
Slide 13: Key Financial Metrics: Quarterly Trend
Key Financial Metrics: Quarterly Trend R&D (INR mn) Capex (INR mn) Net debt/ Equity 5,000 4,481 4,344 15.0% 2,000 1,848 15.0% 0.08 4,500 4,255 1,800 0.07 13.0% 13.0% 0.07 4,000 3,567 3,500 11.0% 1,600 1,449 11.0% 0.06 3,500 1,400 1,241 3,000 9.0% 1,200 1,059 1,117 9.0% 0.05 2,500 8.7% 8.2% 7.7% 7.0%
Slide 14: P&L Highlights Q3 FY25
P&L Highlights Q3 FY25 YoY QoQ Amount in INR mn Q3’FY25 % of Sales Q3’FY24 % of Sales Q2’FY25 % of Sales Growth Growth Net Sales 56,186 100.00% 50,799 100.00% 10.6% 54,970 100.00% 2.2% Other operating income 1,492 2.7% 1,175 2.3% 27.0% 1,757 3.2% -15.1% Total revenue 57,677 102.7% 51,974 102.3% 11.0
Slide 15: P&L Highlights 9M FY25
P&L Highlights 9M FY25 YoY Amount in INR mn 9M’FY25 % of Sales 9M’FY24 % of Sales Growth Net Sales 166,299 100.0% 147,612 100.0% 12.7% Other operating income 4,109 2.5% 2,888 2.0% 42.3% Total revenue 170,408 102.5% 150,500 102% 13.2% Gross Profit (excl. other operating 114,739 69.0% 96,916 65.7%* 18
Slide 16: Lupin at a Glance
hd LUPIN Lupin at a ¢
Slide 17: Lupin Today
Lupin Today Operating from a position of strength Global Presence Local Leadership Geographically Diverse (FY24 Sales) 12th Largest in India Pharma 9% Largest Generic 3 rd the US 7th Market Rank 34% INDIA Developed Company (by prescriptions2) Markets (by sales4) (by sales1) 37% Largest Largest US $2
Slide 18: Vision
Vision A pharmaceutical company focused on delivering high quality medicines to patients around the world Global Other United Developed India Region Emerging API States Markets Markets Evolving portfolio and Global operational Delivering innovative pipeline in Complex Global reach and scale as effic
Slide 19: Lupin's ESG Update
Lupin’s ESG Update Progressing steadily in reaching our ambitious long-term ESG targets ESG Goal Status FY 2024 Key Highlights Q3 FY25 Climate 38% GHG Reduction 21% GHG 45 Water Harvesting Structures built, creating a water storage Change 1 by 2030 Reduction potential of 108,543 cubic meters. 50% re
Slide 20: ESG: Ratings update in FY24
ESG: Ratings update in FY24 Committed to accountability and public disclosure of ESG initiatives. Our performance is reflected in year-on-year progress across ESG ratings Agency 2021 2022 2023 2024 Lupin’s ESG Efforts are aligned to Global Frameworks, ESG Ratings and Certifications ESG Score 17 46 6
Slide 21: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Lupin’s S&P Global ESG score moved up to 76 from 69 last year • Humrahi, Lupin’s Patient Support Program for Diabetes Management, won the Excellence in Patient Support Program category at the 14th ELETS Healthcare Innovation Award • Lupin Research Park facility (Pune)
Slide 22: Thank You
Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400055, India Phone: +91 22664 02323 | Fax: +91 22664 02051 lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal facebook.com/LupinWorld/ linkedIn.com/company/lupin